GlassScriptPhysician profile
Latha M Chamarthy
NPI 1871578294
$11,192.97
in general payments reported to CMS, 2019-2025
36 companies · $1,758 in 2025
The $1,758 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,237 · 2020: $376 · 2021: $1,299 · 2022: $1,351 · 2023: $1,155 · 2024: $1,016 · 2025: $1,758.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,843 · Education: $87.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,842.67 |
| Education | $87.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $3,458.81 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,229.50 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $1,171.65 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $717.59 | 2020-2025 | Cinryze, Hyqvia, Cuvitru |
| Glaxosmithkline, LLC. | $613.74 | 2019-2025 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $466.91 | 2020-2025 | |
| Csl Behring | $440.07 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Novartis Pharmaceuticals Corporation | $430.21 | 2019-2025 | |
| Amgen INC. | $396.20 | 2019-2025 | Tezspire |
| Kaleo, INC. | $309.57 | 2019-2023 | Auvi-Q |
| Pfizer INC. | $202.48 | 2019-2025 | |
| Phadia US INC. | $200.87 | 2019-2022 | |
| Pharming Healthcare, INC. | $171.41 | 2021-2023 | Ruconest |
| Blueprint Medicines Corporation | $162.82 | 2023-2024 | Ayvakit |
| Incyte Corporation | $138.87 | 2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $125.70 | 2019-2022 | |
| Grifols USA, LLC | $113.53 | 2024-2025 | Xembify |
| Janssen Pharmaceuticals, INC | $110.84 | 2019 | |
| Covis Pharma Gmbh | $105.10 | 2021 | |
| Galderma Laboratories, L.P. | $99.03 | 2025 | Nemluvio |
| Teva Pharmaceuticals USA, INC. | $83.74 | 2020-2023 | |
| Biocryst US Sales Co., LLC | $60.91 | 2022-2023 | Orladeyo |
| Azurity Pharmaceuticals, INC. | $57.50 | 2025 | Alvesco |
| Ars Pharmaceuticals Operations, INC. | $52.21 | 2025 | Neffy |
| Shire North American Group INC | $39.60 | 2019 | |
| Horizon Therapeutics Plc | $26.83 | 2021 | |
| Octapharma USA, INC. | $25.84 | 2020 | |
| Uswm, LLC | $23.00 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.79 | 2020 | |
| Lilly USA, LLC | $21.60 | 2025 | Ebglyss, Taltz |
| Biocryst Pharmaceuticals, INC. | $20.72 | 2020 | |
| Eyevance Pharmaceuticals LLC | $20.70 | 2021 | |
| Leo Pharma INC. | $20.51 | 2025 | Anzupgo |
| Ionis Pharmaceuticals, INC. | $20.07 | 2025 | Dawnzera |
| Aimmune Therapeutics, INC. | $17.27 | 2021 | |
| Circassia INC. | $15.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Latha Chamarthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.